- Email: [email protected]
4946788 Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
iii
New Patents amounts of denatured picornavirus, such as poliovirus, capsis proteins, in a vaccine, is highly advantageous.
immunoincompetence due to widely spread cancer. The effectiveness of cancer therapy is monitored by monitoring the change in levels of the immunosuppressivehaptoglobin variant factor in the serum from the patient being treated.
4946677 PREPARATIONS ACTIVE AGAINST PSEUDOMONAS AERUGINOSA INFECTIONS AND METHODS OF PRODUCING THEM Friedric Dorner, Johann Eibl, Vienna, Austria assigned to lmmuno Aktiengesellschaft fur Chemisch-Medizinische Produkte Preparations active against Pseudomonas aeruginosa Infections, namely vaccines for active immunization as well as preparations containing antibodies and destined for passive protection; as well as methods for the production thereof. The vaccines contain protective flagellar (H) antigens of the serotype a and b, which consist of monomeric components, each monomeric component is composed of certain amino acids having a certain N-terminal amino acid sequence and has a certain molecular weight. The vaccines are made from purified flagellar (H) antigen solutions. The immunoglobulin-G-containing preparations contain flagellar (H) antibodies obtained from the blood plasma of human donors or mammals immunized with protective flagellar (H) antigens. They can be purified by methods of affinity chromatography.
4946774 PROCESS FOR DETECTING CANCER AND FOR MONITORING THE EFFECTIVENESS OF CANCER THERAPY Se-Kyung Oh assigned to Trustees of Boston University A process for detecting cancer in a human patient is provided wherein a blood serum is recovered from the patient and is reacted with a monoclonai antibody comprising antihaptoglobin variant under conditions to effect an immunoreaction when an immunosuppressive factor having a molecular weight of about 50K Daltons is present in the serum. The presence ofimmunosuppressive factor at concentration levels substantially exceeding normal concentration levels indicates the existence of
49467~ PURIFIED IMMUNOGLOBULINRELATED FACTOR, NOVEL MONOCLONAL ANTIBODIES, HYBRIDOMA CELL LINES, PROCESSES AND APPLICATIONS Gu Delespesse, Winnipeg, Canada assigned to Ciba-Geigy Corporation The invention relates to novel purified human immunoglobulinE binding factors (IgE-BFs), its individual optionally glycosylated proteins, and fragments thereof, processes for the purification of IgE-BFs, novel monoclonal antibodies to lymphocyte cellular receptors for lgE (Fc epsilonR) crossreacting with IgE-Fs, derivatives thereof, processes for the preparation of these antibodies and their derivatives, hybridoma cell lines that produce these antibodies, processes for the preparation of said hybridoma cell lines, the use of the monoclonal antibodies and their derivatives for the qualitative and quantitative determination of IgE-BFs, test kits containing the monoclonal antibodies and/or their derivatives, the use of the monoclonal antibodies for the purification of IgE-BFs, the use of purified IgE-BFs, its individual optionally glycosylated proteins and/or fragments thereof for the prevention and/or treatment of allergy, and to pharmaceutical preparations containing them. IgE-BFs and monoclonal antibodies reacting with IgE-BF are important for the diagnosis and therapy of allergic diseases.
4946796 METHOD
OF IMMUNOASSAY
Daniel Collet-Cassart, Carl-Gustav Magnusson, Pierre L Masson, Kraainem, Belgium assigned to International Institute of Cellular & Molecular Pathology A biological fluid from a first animal species (e.g. human serum) is assayed for an immunogen therein by mixing with the fluid (Ig-minus-Fc) fragments of an immunoglobulinfrom a second animal species (e.g. rabbit), the immunoglobulin being immunospecific to the immunogen or
New Patents amounts of denatured picornavirus, such as poliovirus, capsis proteins, in a vaccine, is highly advantageous.
immunoincompetence due to widely spread cancer. The effectiveness of cancer therapy is monitored by monitoring the change in levels of the immunosuppressivehaptoglobin variant factor in the serum from the patient being treated.
4946677 PREPARATIONS ACTIVE AGAINST PSEUDOMONAS AERUGINOSA INFECTIONS AND METHODS OF PRODUCING THEM Friedric Dorner, Johann Eibl, Vienna, Austria assigned to lmmuno Aktiengesellschaft fur Chemisch-Medizinische Produkte Preparations active against Pseudomonas aeruginosa Infections, namely vaccines for active immunization as well as preparations containing antibodies and destined for passive protection; as well as methods for the production thereof. The vaccines contain protective flagellar (H) antigens of the serotype a and b, which consist of monomeric components, each monomeric component is composed of certain amino acids having a certain N-terminal amino acid sequence and has a certain molecular weight. The vaccines are made from purified flagellar (H) antigen solutions. The immunoglobulin-G-containing preparations contain flagellar (H) antibodies obtained from the blood plasma of human donors or mammals immunized with protective flagellar (H) antigens. They can be purified by methods of affinity chromatography.
4946774 PROCESS FOR DETECTING CANCER AND FOR MONITORING THE EFFECTIVENESS OF CANCER THERAPY Se-Kyung Oh assigned to Trustees of Boston University A process for detecting cancer in a human patient is provided wherein a blood serum is recovered from the patient and is reacted with a monoclonai antibody comprising antihaptoglobin variant under conditions to effect an immunoreaction when an immunosuppressive factor having a molecular weight of about 50K Daltons is present in the serum. The presence ofimmunosuppressive factor at concentration levels substantially exceeding normal concentration levels indicates the existence of
49467~ PURIFIED IMMUNOGLOBULINRELATED FACTOR, NOVEL MONOCLONAL ANTIBODIES, HYBRIDOMA CELL LINES, PROCESSES AND APPLICATIONS Gu Delespesse, Winnipeg, Canada assigned to Ciba-Geigy Corporation The invention relates to novel purified human immunoglobulinE binding factors (IgE-BFs), its individual optionally glycosylated proteins, and fragments thereof, processes for the purification of IgE-BFs, novel monoclonal antibodies to lymphocyte cellular receptors for lgE (Fc epsilonR) crossreacting with IgE-Fs, derivatives thereof, processes for the preparation of these antibodies and their derivatives, hybridoma cell lines that produce these antibodies, processes for the preparation of said hybridoma cell lines, the use of the monoclonal antibodies and their derivatives for the qualitative and quantitative determination of IgE-BFs, test kits containing the monoclonal antibodies and/or their derivatives, the use of the monoclonal antibodies for the purification of IgE-BFs, the use of purified IgE-BFs, its individual optionally glycosylated proteins and/or fragments thereof for the prevention and/or treatment of allergy, and to pharmaceutical preparations containing them. IgE-BFs and monoclonal antibodies reacting with IgE-BF are important for the diagnosis and therapy of allergic diseases.
4946796 METHOD
OF IMMUNOASSAY
Daniel Collet-Cassart, Carl-Gustav Magnusson, Pierre L Masson, Kraainem, Belgium assigned to International Institute of Cellular & Molecular Pathology A biological fluid from a first animal species (e.g. human serum) is assayed for an immunogen therein by mixing with the fluid (Ig-minus-Fc) fragments of an immunoglobulinfrom a second animal species (e.g. rabbit), the immunoglobulin being immunospecific to the immunogen or